- Home
- TBPH vs PBT Comparison
TBPH vs PBT Comparison
Compare TBPH & PBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- PBT
- Stock Information
- Founded
- TBPH 2013
- PBT 1980
- Country
- TBPH United States
- PBT United States
- Employees
- TBPH N/A
- PBT N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- PBT Oil & Gas Production
- Sector
- TBPH Health Care
- PBT Energy
- Exchange
- TBPH Nasdaq
- PBT Nasdaq
- Market Cap
- TBPH 464.5M
- PBT 508.5M
- IPO Year
- TBPH N/A
- PBT N/A
- Fundamental
- Price
- TBPH $10.73
- PBT $12.16
- Analyst Decision
- TBPH Buy
- PBT
- Analyst Count
- TBPH 4
- PBT 0
- Target Price
- TBPH $14.50
- PBT N/A
- AVG Volume (30 Days)
- TBPH 319.2K
- PBT 314.6K
- Earning Date
- TBPH 08-04-2025
- PBT 01-01-0001
- Dividend Yield
- TBPH N/A
- PBT 4.53%
- EPS Growth
- TBPH N/A
- PBT N/A
- EPS
- TBPH N/A
- PBT 0.48
- Revenue
- TBPH $65,266,000.00
- PBT $24,140,674.00
- Revenue This Year
- TBPH $43.53
- PBT N/A
- Revenue Next Year
- TBPH N/A
- PBT N/A
- P/E Ratio
- TBPH N/A
- PBT $24.71
- Revenue Growth
- TBPH 6.11
- PBT N/A
- 52 Week Low
- TBPH $7.44
- PBT $8.01
- 52 Week High
- TBPH $11.82
- PBT $14.26
- Technical
- Relative Strength Index (RSI)
- TBPH 56.31
- PBT 68.37
- Support Level
- TBPH $10.44
- PBT $11.92
- Resistance Level
- TBPH $11.00
- PBT $12.34
- Average True Range (ATR)
- TBPH 0.30
- PBT 0.30
- MACD
- TBPH -0.05
- PBT 0.02
- Stochastic Oscillator
- TBPH 14.81
- PBT 75.00
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.